SYNERGISTIC EFFECT OF THE COMBINED ACTION OF TARGETED AND PHOTODYNAMIC THERAPY ON HER2-POSITIVE BREAST CANCER

I. V. Balalaeva; Балалаева И. В.; L. V. Krylova; Крылова Л. В.; M. A. Karpova; Карпова М. А.; A. A. Shulga; Шульга А. А.; E. V. Konovalova; Коновалова Е. В.; E. L. Guryev; Гурьев Е. Л.; S. M. Deyev; Деев С. М.

doi:10.31857/S268673892270007X

SYNERGISTIC EFFECT OF THE COMBINED ACTION OF TARGETED AND PHOTODYNAMIC THERAPY ON HER2-POSITIVE BREAST CANCER

Autores: Balalaeva I.V.¹, Krylova L.V.¹, Karpova M.A.¹, Shulga A.A.², Konovalova E.V.², Guryev E.L.¹, Deyev S.M.²^,3
Afiliações:
1. Lobachevsky State University of Nizhny Novgorod
2. Shemyakin-Ovchinnikov Institute of Bioorganic Chemistry, Russian Academy of Sciences
3. I.M. Sechenov First Moscow State Medical University
Edição: Volume 508, Nº 1 (2023)
Páginas: 48-52
Seção: Articles
URL: https://vestnik.nvsu.ru/2686-7389/article/view/651150
DOI: https://doi.org/10.31857/S268673892270007X
EDN: https://elibrary.ru/MUGOWP
ID: 651150

Citar

Texto integral

Acesso aberto
Acesso é fechado

Acesso está concedido
Acesso é fechado

Somente assinantes

Resumo
Sobre autores
Bibliografia
Arquivos suplementares
Estatísticas

Resumo

Development of combined schemes for the treatment of oncological diseases is a promising strategy to improve the effectiveness of antitumor therapy. This paper shows the fundamental possibility of multiplying the antitumor effect by combining targeted and photodynamic therapy. It has been demonstrated that sequential treatment of HER-2 positive breast cancer cells with the targeted toxin DARPin-LoPE and the photoactive compound Photodithazine leads to a synergistic enhancement of their effect. In the future, this approach is intended to achieve the maximum therapeutic effect while minimizing the risks of negative side effects.

Palavras-chave

targeted therapy, recombinant anticancer toxin, DARPin-LoPE, photodynamic therapy, Photodithazine, breast cancer, receptor HER2

Bibliografia

Harbeck N., Penault-Llorca F., Cortes J., et al. // Nature Reviews Disease Primers. 2019. V. 5. № 66.
Gerber D.E. // American Family Physician. 2008. V. 77. № 3. P. 311–319.
Padma V.V. // Biomedicine (Taipei). 2015. V. 5. № 4. P. 19.
Iqbal N., Iqbal N. // Molecular Biology International. 2014.
Higgins M.J., Baselga J. // Journal of Clinical Investigation. 2011. V. 121. № 10. P. 3797–3803.
Tolmachev V.M., Chernov V.I., Deyev S.M. // Russ. Chem. Rev. 2022. V. 91. RCR5034.
Sokolova E.A., Shilova O.N., Kiseleva D.V., et al. // International Journal of Molecular Sciences. 2019. V. 20. № 10.
Shapira A., Benhar I. // Toxins (Basel). 2010. V. 2. № 11. P. 2519–2583.
Sabnis A.J., Bivona T.G. // Trends in Molecular Medicine. 2019. V. 25. №3. P. 185–197.
Plana D., Palmer A.C., Sorger P.K. // Cancer Discovery. 2022. V. 12. № 3. P. 606–624.
Boshuizen J., Peeper D.S. // Molecular Cell. 2020. V. 78. № 6. P. 1002–1018.
Agostinis P., Berg K., Cengel K.A. et al. // CA: A Cancer Journal for Clinicians. 2011. V.61. №4. P. 250–281.
Shramova E.I., Chumakov S.P., Shipunova V.O., et al. // Light Sci. Appl. 2022. V. 11. № 1. P. 38.
Mishchenko T., Balalaeva I., Gorokhova A., et al. // Cell Death & Disease. 2022. V. 13. № 5. P. 455.
Weldon J.E., Pastan I. // The FEBS Journal. 2011. V. 278. № 23. P. 4683–4700.
Shilyagina N.Y., Plekhanov V.I., Shkunov I.V. et al. // Sovremennye Tehnologii v Medicine. 2014. V. 8. P. 15–24.
Guryev E.L., Volodina N.O., Shilyagina N.Y., et al. // Proceedings of the National Academy of Sciences. 2018. V. 115. № 39. P. 9690–9695.
Chu P.L., Shihabuddeen W.A., Low K.P., et al. // Photodiagnosis and Photodynamic Therapy. 2019. V. 27. P. 367–374.
Bhuvaneswari R., Ng Q.F., Thong P.S., Soo K.C. // Oncotarget. 2015. V. 6. № 15. P. 13487–13505.